Search

The new center brings together scientists and clinicians working in various fields who will use the power of imaging to speed research and innovations in cancer care.

A new laboratory tool will allow researchers to study the progression from normal cells to myelodysplastic syndromes to an aggressive type of leukemia.

A blood-based test identifies patients in whom immunotherapy may ‘LAG.’

Eight scientists are poised to receive their doctorates and embark on careers tackling problems in human disease through biomedical research. Their years of dedication and training will be recognized on May 18, 2022, when they will be awarded their PhD degrees from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK). This year’s commencement marks the school’s 11th graduating class since admitting its first students in 2006.

The MSK team’s goal was to get at the underlying defects in cells that these mutations cause.

Laboratory studies have revealed an explanation for why androgen-deprivation therapy makes radiation therapy more effective in the treatment of high-risk prostate cancer.

A multi-institutional team led by investigators from Memorial Sloan Kettering Cancer Center has published a study that provides new insight into genetic changes that make some forms of glioblastoma, the most common type of primary brain cancer, more aggressive than others and explains why they may not respond to certain therapies.

Cancer biologist Robert Benezra explains angiogenesis, the process by which new blood vessels form, and how it relates to cancer research.